You are here

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Last updated on May 23, 2018

FOR MORE INFORMATION
Study Location
Alabama Oncology
Alabaster, Alabama, 35007 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Ovarian Cancer
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Histologically confirmed Stage III-IV epithelial ovarian, fallopian tube, or primary
peritoneal cancer, including malignant mixed Müllerian tumors with high grade serous
component

- Patients must be candidates for platinum based chemotherapy and previously untreated

- Patients must have completed a surgical debulking procedure, or be candidates for
neoadjuvant chemotherapy

- Availability of an archival formalin fixed, paraffin embedded (FFPE) tumor tissue
block or a minimum of 15 slides

- ECOG PS 0-1

- Adequate hematological, renal, and liver function

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Non epithelial tumors or ovarian tumors with low malignant potential (ie, borderline
tumors) or mucinous tumors

- Prior systemic anti-cancer treatment for EOC, FTC, or PPC including prior
immunotherapy with IL 2, IFN ?, or anti PD 1, anti PD L1, anti PD L2, anti CD137, or
anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody (including
ipilimumab), or any other antibody or drug specifically targeting T cell co
stimulation or immune checkpoint pathways

- Patients for whom, in the opinion of the Investigator, there is clinical benefit to
administer bevacizumab as a first-line treatment and for whom bevacizumab is approved
and available in this setting.

- Cancer for which intraperitoneal cytotoxic chemotherapy is planned

- Active autoimmune disease (some exceptions include diabetes type I, vitiligo,
psoriasis, hypo- or hyperthyroidism not requiring immunosuppressive treatment)

NCT02718417
Pfizer
Active, not recruiting
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Non-Small Cell Lung Cancer, Urothelial Cancer
NCT03472560
All Genders
18+
Years
Multiple Sites
Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
A Randomized, Open-label, Multicenter, Phase 3 Study To Evaluate The Efficacy And Safety Of Avelumab (msb0010718c) In Combination With And/or Following Chemotherapy In Patients With Previously Untreated Epithelial Ovarian Cancer Javelin Ovarian 100

This is a Phase 3, open-label, international, multi-center, efficacy, and safety study of avelumab in combination with and/or following platinum-based chemotherapy. Eligible patients must have previously untreated, histologically confirmed Stage III-IV epithelial ovarian (EOC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) and be candidates for platinum-based chemotherapy.

The primary purpose of the study is to demonstrate if avelumab given as single agent in the maintenance setting following frontline chemotherapy or in combination with carboplatin/paclitaxel is superior to platinum-based chemotherapy alone followed by observation in this population of newly diagnosed ovarian cancer patients.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Masking: None (Open Label)
Primary Purpose: Treatment
Ovarian Cancer
  • Drug: carboplatin
    Given Q3W during chemotherapy phase
  • Drug: paclitaxel
    Investigator choice of weekly or Q3W during chemotherapy phase
  • Drug: Avelumab
    Given Q3W in combination with carboplatin/paclitaxel during chemotherapy portion
  • Drug: Avelumab
    Given as single agent in maintenance portion Q2W
  • Active Comparator: Arm A
    Chemotherapy followed by observation
    Interventions:
    • Drug: carboplatin
    • Drug: paclitaxel
  • Experimental: Arm B
    Chemotherapy followed by avelumab in maintenance
    Interventions:
    • Drug: carboplatin
    • Drug: paclitaxel
    • Drug: Avelumab
  • Experimental: Arm C
    Chemotherapy in combination with avelumab followed by avelumab in maintenance
    Interventions:
    • Drug: carboplatin
    • Drug: paclitaxel
    • Drug: Avelumab
    • Drug: Avelumab
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
951
December 5, 2021
September 6, 2019   (Final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • Histologically confirmed Stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, including malignant mixed Müllerian tumors with high grade serous component
  • Patients must be candidates for platinum based chemotherapy and previously untreated
  • Patients must have completed a surgical debulking procedure, or be candidates for neoadjuvant chemotherapy
  • Availability of an archival formalin fixed, paraffin embedded (FFPE) tumor tissue block or a minimum of 15 slides
  • ECOG PS 0-1
  • Adequate hematological, renal, and liver function

Key Exclusion Criteria:

  • Non epithelial tumors or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors
  • Prior systemic anti-cancer treatment for EOC, FTC, or PPC including prior immunotherapy with IL 2, IFN ?, or anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways
  • Patients for whom, in the opinion of the Investigator, there is clinical benefit to administer bevacizumab as a first-line treatment and for whom bevacizumab is approved and available in this setting.
  • Cancer for which intraperitoneal cytotoxic chemotherapy is planned
  • Active autoimmune disease (some exceptions include diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroidism not requiring immunosuppressive treatment)
Sexes Eligible for Study: Female
Gender Based Eligibility: Yes
18 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 [email protected]
Bulgaria,   Canada,   Croatia,   Estonia,   Germany,   Hong Kong,   Hungary,   Ireland,   Italy,   Japan,   Korea, Republic of,   Latvia,   Mexico,   Netherlands,   Poland,   Romania,   Russian Federation,   Singapore,   Slovakia,   Switzerland,   Taiwan,   Turkey,   Ukraine,   United Kingdom,   United States
 
 
NCT02718417
B9991010
2015-003239-36 ( EudraCT Number )
JAVELIN OVARIAN 100 ( Other Identifier: Alias Study Number )
Yes
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Study Chair: Bradley Monk, MD Department of Obstetrics and Gynecology University of Arizona Cancer Center, USA
Study Chair: Jonathan Ledermann, MD UCL Cancer Institute, UK
Pfizer
November 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now